title: Efficacy and safety of tenecteplase in ST elevation myocardial infarction patients from the Elaxim Indian Registry.
abstract: OBJECTIVE
  to study the efficacy and safety of indigenously developed tenecteplase injection in the management of Indian STEMI patients in clinical practice.
  
  
  METHODS
  post-licensure, observational, prescription event monitoring study.
  
  
  RESULTS
  2100 patients received weight-adjusted tenecteplase injection. More than 90% patients received aspirin, clopidogrel, and enoxaparin/heparin. Clinically successful thrombolysis was reported in 86.71%, in-hospital mortality was 3.48%. The adverse events recorded were comparable with previously published data. Any bleeding (excluding intra-cranial hemorrhage) was seen in 4.62% patients which was reported in 0.90% patients of which 47.34% patients had also received GpIIb/IIIa inhibitors.
  
  
  CONCLUSIONS
  This study confirms the efficacy and safety of indigenous tenecteplase in Indian STEMI patients.
authors.affiliation: Department of Cardiology, St. John's Medical College & Hospital, Bangalore, Karnataka, India. cardioresearch@gmail.com
authors.forename: S S
authors.initials: SS
authors.lastname: Iyengar
authors.forename: Tiny
authors.initials: T
authors.lastname: Nair
authors.forename: I
authors.initials: I
authors.lastname: Sathyamurthy
authors.forename: J S
authors.initials: JS
authors.lastname: Hiremath
authors.forename: U
authors.initials: U
authors.lastname: Jadhav
authors.forename: D
authors.initials: D
authors.lastname: Kumbla
authors.forename: R K
authors.initials: RK
authors.lastname: Jain
authors.forename: M
authors.initials: M
authors.lastname: Srinivasan
authors.forename: P K
authors.initials: PK
authors.lastname: Sahoo
authors.forename: Kamaldeep
authors.initials: K
authors.lastname: Chawla
authors.forename: V K
authors.initials: VK
authors.lastname: Katiyal
mesh_terms: D000368:Aged; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D007194:India; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy*; D012042:Registries; D000077785:Tenecteplase; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator; D000077785:Tenecteplase